Single Dose PCSK9 Inhibitor to Improve Cardiovascular Outcomes After PCI: A Pilot Study
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 352 participants.
Also called NCT07084259
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 352 participants
- Registry
-
NCT07084259
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07084259. Randomized; no masking; primary purpose treatment. Start 2025-07 (anticipated); primary completion 2030-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Single Dose PCSK9 Inhibitor to Improve Cardiovascular Outcomes After PCI: A Pilot Study
- Acronym
- HANYANG-PICK
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- PCSK9 inhibitor
- Intervention (Drug)
- Standard Lipid-Lowering Therapy
- Lead sponsor
- Hanyang University Seoul Hospital
- Collaborator
- DOTTER Inc.
Record details
- Record id
cardio:ct-nct07084259- Content hash
7dac41e22c19b72d23f317e88c11c90e22d8841abed8bb3cc8951ca2c345d515